Welcome!

News Feed Item

Dr. Jeanne M. Novak, President & CEO Of CBR International Corp.®, To Attend World Health Organization (WHO) Meeting To Address Leading Experimental Treatments And Vaccines For The Ebola Virus, September 4 - 5, 2014, Geneva, Switzerland

CBR International's Scientific Experts Supporting Mapp Biopharmaceutical Pertaining to ZMAPP™

BOULDER, Colo., Sept. 2, 2014 /PRNewswire/ -- Dr. Jeanne M. Novak, President and CEO of Boulder, Colorado-based CBR International Corp.®, a full-service biopharmaceutical product, clinical, medical device and regulatory development and compliance group, has been invited by Dr. Larry Zeitlin, President of Mapp Biopharmaceutical to attend the World Health Organization's Investigational Treatment for Ebola conference in Geneva, Switzerland, September 4 – 5. Over the last several months, CBR International's expert team of clinical, regulatory and scientific consultants has been supporting and collaborating with Mapp Biopharmaceutical, Inc., the San Diego-based biotech company responsible for developing ZMappTM, the monoclonal antibody cocktail that has been employed for compassionate use in the current Ebola outbreak.

Working side-by-side with Mapp Biopharmaceutical, Inc.,  Kentucky Bioprocessing (KBP), Emory University Hospital (Atlanta), ELWA Hospital (Paynesville City/Monrovia, Liberia), London's Royal Free Hospital (UK) and the U.S. Food and Drug Administration (FDA), CBR International has helped to ensure that the proper dosing, safety monitoring and all regulatory procedures were followed for the administration of ZMapp.

"CBR International Corp. has been committed to supporting Mapp Biopharmaceutical during the emergency use of the investigational product," said Dr. Jeanne M. Novak, President and CEO of CBR International Corp. "We will continue to support Mapp throughout its ongoing clinical development while also lending our expertise to the myriad of other affiliated health and regulatory organizations during this crisis."

Dr. Kevin Whaley, CEO of Mapp Biopharmaceutical noted that, "Without the collaboration and support of CBR International associates, especially Dr. Jeanne M. Novak, Dr. Miles Brennan, Mr. Kevin Hennegan, Dr. Tara Nyhuis, Dr. James Merritt, and Dr. Dana Weinberger, patients may not have had the opportunity to volunteer to receive ZMapp."

The WHO meeting in Geneva will address leading experimental treatments and vaccines for Ebola, including potential risks and benefits, short- and long-term availability, potential use and key considerations for deployment in West Africa, as well as clinical testing and ethics. Its goal is to help develop strategies to pave the road for future Ebola preparedness.

About Dr. Jeanne M. Novak
Dr. Jeanne M. Novak founded CBR International Corp. in 1999 (originally Colorado BioReg). She is an internationally-recognized authority in the biotechnology and pharmaceutical industries and is currently consulting in numerous product development areas including recombinant biotechnology, naturally-derived products, cell and gene therapy, devices and vaccines. She is an author, lecturer and strategic development advisor to industry executives worldwide.

Additionally, Dr. Novak has almost 20 years of experience in product and assay development and validation, clinical trial design and oversight, quality assurance systems development, cGMP manufacturing and compliance and global regulatory development to advise cost and time-optimized development for new and established biotech and pharma companies.

Prior to founding CBR International, Dr. Novak served as Senior Scientist in the Center for Biologics Evaluation and Research (CBER) responsible for several programs and policy development.  Before joining the FDA, Dr. Novak conducted scientific research in the area of recombinant vaccine development at United States Army Medical Research Institute of Infectious Diseases.

Dr. Novak received a Ph.D. in Experimental Pathology (Cell Biology) and Immunology and a B.S. in Biology from the University of Utah.

About CBR International Corp.
CBR International Corp. is a full-service product, clinical, and strategic regulatory group dedicated to providing comprehensive product development services to the biotechnology, pharmaceutical, and device industries worldwide. The Company's expert staff of scientists is experienced in an all-encompassing range of indications for drugs, novel antibodies, recombinant protein therapeutics, small molecules, vaccines, cell therapy, devices and combination products throughout all phases of program development and commercialization. For more information, please visit www.cbrintl.com.

SOURCE CBR International Corp.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists loo...
"When we talk about cloud without compromise what we're talking about is that when people think about 'I need the flexibility of the cloud' - it's the ability to create applications and run them in a cloud environment that's far more flexible,” explained Matthew Finnie, CTO of Interoute, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
The financial services market is one of the most data-driven industries in the world, yet it’s bogged down by legacy CPU technologies that simply can’t keep up with the task of querying and visualizing billions of records. In his session at 20th Cloud Expo, Karthik Lalithraj, a Principal Solutions Architect at Kinetica, discussed how the advent of advanced in-database analytics on the GPU makes it possible to run sophisticated data science workloads on the same database that is housing the rich...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists discussed...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...